A DoenÃa Periodontal (DP) à uma doenÃa inflamatÃria que se relaciona com diversas condiÃÃes sistÃmicas, tais como a osteoporose. A osteoporose induzida por glicocorticÃide (OPIG) à a causa mais importante de osteoporose secundÃria. A Atorvastatina (ATV), fÃrmaco hipolipemiante, apresenta efeitos pleiotrÃpicos, anti-inflamatÃrio e anabÃlico Ãsseo, que podem ser relevantes em prevenir a perda Ãssea em casos de OPIG e DP.O objetivo deste estudo foi avaliar os efeitos da ATV na reabsorÃÃo Ãssea alveolar em ratas com OPIGsubmetidasà DP. AOPIGfoi induzida pela administraÃÃo de dexametasona 7 mg/kg 1x/semana por 5 semanas (i.m.). DPfoi induzida por ligadura ao redor do segundo molar superior esquerdo de ratas por 11 dias. Vinte e quatro animais foram divididos em 4 grupos de 6 animais cada: DP (SHAM OPIG [Salina 0,9% 0,5 ml â i.m.]+DP + Salina [0,9% 2 ml â v.o]); OPIG (DEXA + SHAM DP+Salina); OPIG+ DP (DEXA + DP + Salina); ATV (DEXA + DP + ATV [27 mg/kg â v.o.]) atà eutanÃsia. Os parÃmetros avaliados foram: perda Ãssea alveolar (anÃlise macroscÃpica e radiogrÃfica); expressÃo de citocinas (TNF-&#945; e IL-1&#946;) no tecido gengival; leucograma; nÃveis sÃricos de transaminases, fosfatase alcalina total (FAT) e Ãssea (FAO). AATV preveniu a perda Ãssea em 37,84% (p<0,05).As anÃlises radiogrÃficas corroboraram os achados macroscÃpicos.ATV reduziu a expressÃo deTNF-&#945; (54,88%) e IL-1&#946; (62,55%)na gengiva (p<0,05) e reverteu a neutrofilia (p<0,05). Nenhuma diferenÃa estatÃstica foi observadaquanto aosnÃveis sÃricos de transaminases.ATV (27 mg/kg) aumentou a concentraÃÃo sÃrica de FAT e FAO, quando comparada aogrupo OPIG+DP.Em suma podemos concluir que aATV previniua perda Ãssea alveolar emanimais submetidos a OPIG+DP, por meio de efeito anti-reabsortivo, anti-inflamatÃrio e anabÃlico Ãsseo. / Periodontal disease (PD) is an inflammatory disease that has relationship with several systemic conditions, such as osteoporosis. Glucocorticoid-induced osteoporosis (GIOP) is the main cause of secondary osteoporosis. Atorvastatin (ATV), a hypolipemiant drug, presents pleotropic effects, anti-inflammatory and bone anabolism, which may be relevant in order to prevent bone loss in cases of GIOP and PD. The aim of this study was to evaluate the effects of ATV on alveolar bone loss in rats with GIOP and subjected to periodontitis. GIOP was induced by administration of desametaxone 1 mg/kg 1x/week for 5 weeks (i.m.). PD was induced by ligature around the second left upper molar of rats for 11 days. Twenty-fouranimals were divided in 4 groups of 6 animals each: PD (SHAM GIOP [0,9% Saline 0.5 ml â i.m.] +PD + Saline [0.9% 2 ml â orally]);GIOP (DEXA+SHAM PD+Saline); GIOP + PD (DEXA+PD+Saline); ATV (DEXA + PD + ATV [27 mg/kg â orally]) until euthanasia. The parameters evaluated were: alveolar bone loss (macroscopic and radiographic analysis); cytokine expression on gingival tissue (TNF-&#945; and IL-1&#946;); serum levels of transminases, total alkaline phosphatase (TALP) and bone-specific alkaline fosfatase (BALP). ATV prevented bone loss by 34.84% (p<0.05). The radiographic analysis corroborated the macroscopic findings. ATV reduced the expression of TNF-&#945; (54.88%) and IL-1&#946; (62.55%) in gingival tissue(p<0,05). No statistical difference was observed on serum levels of transminases. ATV (27 mg/kg) raised serum concentration of TALP and BALP when compared to GIOP+PD. In summary, we can conclude that ATV prevented alveolar bone loss in animals subjected to GIOP+PD, through anti-resoprtive, anti-inflammatory and bone anabolic effects